{"title":"Intravesikales Gemcitabin-Abgabesystem beim muskelinvasiven Blasenkarzinom","authors":"","doi":"10.1055/a-2253-1472","DOIUrl":"https://doi.org/10.1055/a-2253-1472","url":null,"abstract":"","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140276120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prostatakrebs: Neu entwickelter Hemmstoff zeigt großes Potenzial","authors":"","doi":"10.1055/a-2189-6656","DOIUrl":"https://doi.org/10.1055/a-2189-6656","url":null,"abstract":"","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140274670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neue Therapiestrategien beim HER2-positiven metastasierten Mammakarzinom","authors":"","doi":"10.1055/a-2253-1323","DOIUrl":"https://doi.org/10.1055/a-2253-1323","url":null,"abstract":"","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140278997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Urothelkarzinom des oberen Harntrakts: Detektion anhand von Urinproben möglich","authors":"","doi":"10.1055/a-2253-1453","DOIUrl":"https://doi.org/10.1055/a-2253-1453","url":null,"abstract":"","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140084677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Adagrasib bei KRAS-G12C-mutierten kolorektalen Karzinomen effektiv","authors":"","doi":"10.1055/a-2253-1549","DOIUrl":"https://doi.org/10.1055/a-2253-1549","url":null,"abstract":"","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140269216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Blasenerhaltende multimodale Therapiekonzepte","authors":"Oliver J. Ott","doi":"10.1055/a-1980-7937","DOIUrl":"https://doi.org/10.1055/a-1980-7937","url":null,"abstract":"","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140276663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annika S Behrens, Lena Wurmthaler, F. Heindl, Paul Gass, Lothar Häberle, B. Volz, C. Hack, Julius Emons, R. Erber, A. Hartmann, Matthias W. Beckmann, M. Ruebner, W. Dougall, Peter A. Fasching, H. Huebner, Michael F. Press
The receptor activator of nuclear factor-κB (RANK) pathway was associated with the pathogenesis of breast cancer. Several studies attempted to link the RANK/RANKL pathway to prognosis; however, with inconsistent outcomes. We aimed to further contribute to the knowledge about RANK/RANKL as prognostic factors in breast cancer. Within this study, protein expression of RANK and its ligand, RANKL, in the tumor tissue was analyzed in association with disease-free survival (DFS) and overall survival (OS) in a study cohort of patients with early breast cancer.607 samples of female primary and early breast cancer patients from the Bavarian Breast Cancer Cases and Controls Study were analyzed to correlate the RANK and RANKL expression with DFS and OS. Therefore, expression was quantified using immunohistochemical staining of a tissue microarray. H-scores were determined with the cut-off value of 8.5 for RANK and 0 for RANKL expression, respectively.RANK and RANKL immunohistochemistry were assessed by H-score. Both biomarkers did not correlate (ρ = −0.04). According to molecular subtypes, triple-negative tumors and HER2-positive tumors showed a higher number of RANK-positive tumors (H-score ≥ 8.5), however, no subtype-specific expression of RANKL could be detected. Higher RANKL expression tended to correlate with a better prognosis. However, RANK and RANKL expression could not be identified as statistically significant prognostic factors within the study cohort.Tumor-specific RANK and RANKL expressions are not applicable as prognostic factors for DFS and OS, but might be associated with subtype-specific breast cancer progression.
核因子κB受体激活剂（RANK）通路与乳腺癌的发病机制有关。一些研究试图将 RANK/RANKL 通路与预后联系起来，但结果并不一致。我们的目的是进一步加深对作为乳腺癌预后因素的RANK/RANKL的了解。在这项研究中，我们分析了肿瘤组织中 RANK 及其配体 RANKL 的蛋白表达与早期乳腺癌患者队列中的无病生存期（DFS）和总生存期（OS）的关系。我们分析了来自巴伐利亚乳腺癌病例与对照研究（Bavarian Breast Cancer Cases and Controls Study）的 607 例女性原发性乳腺癌和早期乳腺癌患者样本，以便将 RANK 和 RANKL 的表达与无病生存期和总生存期联系起来。因此，通过组织芯片的免疫组化染色对表达进行了量化。RANK和RANKL免疫组化的H-score值分别为8.5和0。这两种生物标志物没有相关性（ρ = -0.04）。根据分子亚型，三阴性肿瘤和HER2阳性肿瘤中RANK阳性肿瘤的数量较多（H-score ≥ 8.5），但未检测到亚型特异性的RANKL表达。RANKL表达越高，预后越好。肿瘤特异性RANK和RANKL表达不能作为DFS和OS的预后因素，但可能与亚型特异性乳腺癌进展有关。
{"title":"RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer","authors":"Annika S Behrens, Lena Wurmthaler, F. Heindl, Paul Gass, Lothar Häberle, B. Volz, C. Hack, Julius Emons, R. Erber, A. Hartmann, Matthias W. Beckmann, M. Ruebner, W. Dougall, Peter A. Fasching, H. Huebner, Michael F. Press","doi":"10.1055/a-2257-9565","DOIUrl":"https://doi.org/10.1055/a-2257-9565","url":null,"abstract":"The receptor activator of nuclear factor-κB (RANK) pathway was associated with the pathogenesis of breast cancer. Several studies attempted to link the RANK/RANKL pathway to prognosis;\u0000 however, with inconsistent outcomes. We aimed to further contribute to the knowledge about RANK/RANKL as prognostic factors in breast cancer. Within this study, protein expression of RANK and\u0000 its ligand, RANKL, in the tumor tissue was analyzed in association with disease-free survival (DFS) and overall survival (OS) in a study cohort of patients with early breast cancer.607 samples of female primary and early breast cancer patients from the Bavarian Breast Cancer Cases and Controls Study were analyzed to correlate the RANK and RANKL expression with DFS\u0000 and OS. Therefore, expression was quantified using immunohistochemical staining of a tissue microarray. H-scores were determined with the cut-off value of 8.5 for RANK and 0 for RANKL\u0000 expression, respectively.RANK and RANKL immunohistochemistry were assessed by H-score. Both biomarkers did not correlate (ρ = −0.04). According to molecular subtypes, triple-negative tumors and HER2-positive\u0000 tumors showed a higher number of RANK-positive tumors (H-score ≥ 8.5), however, no subtype-specific expression of RANKL could be detected. Higher RANKL expression tended to correlate with a\u0000 better prognosis. However, RANK and RANKL expression could not be identified as statistically significant prognostic factors within the study cohort.Tumor-specific RANK and RANKL expressions are not applicable as prognostic factors for DFS and OS, but might be associated with subtype-specific breast cancer progression.","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140279326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Muzinöses Ovarialkarzinom: Prognose des expansilen und des infiltrativen Subtyps","authors":"","doi":"10.1055/a-2253-1520","DOIUrl":"https://doi.org/10.1055/a-2253-1520","url":null,"abstract":"","PeriodicalId":333101,"journal":{"name":"TumorDiagnostik & Therapie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140272013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：